StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc.

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$920.69−2.65 (-0.29%)

Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –

Regeneron Pharmaceuticals Indirect R&D by Quarter

Indirect R&D — Lab Supplies and Other Research and Development Costs ($M) ($M)

Regeneron Pharmaceuticals Indirect R&D: $76.3M in Q3 2026, up 13.0% from a year earlier. That is the highest of the 34 quarters on record here.

Latest, Q3 2026
76.3
Period ended Sep 30, 2026
Change on a year earlier
+13.0%
67.5 in Q3 2025
History
34 quarters
Since Q2 2018
Sources
31
Documents cited below

Where the Q3 2026 figure comes from

“R&D Expenses Table (FY2026Q3): Lab supplies and other research and development costs | 76.3 | 67.5 | 8.8 | 207.1 | 192.4 | 14.7”

Source: Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗

Reported in Form 10-Q / 10-K MD&A — Research and Development Expenses Summary Table.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedIndirect R&D — Lab Supplies and Other Research and Development Costs ($M) ($M)Year on yearSource
Q3 2026Sep 30, 202676.3+13.0%Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Q2 2026Jun 30, 202671.5+10.2%Form 10-Q (regn-20260630.htm, filed 2026-07-30) ↗
Q1 2026Mar 31, 202659.3-1.2%Form 10-Q (regn-20260331.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 202565.8-0.5%Form 10-K (regn-20251231.htm; 0000872589-26-000034|regn-20260930.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 202567.5+7.1%Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Q2 2025Jun 30, 202564.9+14.9%Form 10-Q (regn-20260630.htm, filed 2026-07-30) ↗
Q1 2025Mar 31, 202560+7.3%Form 10-Q (regn-20260331.htm, filed 2026-04-29) ↗
Q4 2024Dec 31, 202466.1+25.4%Form 10-K (regn-20251231.htm; 0000872589-25-000028|regn-20250930.htm, filed 2026-02-04) ↗
Q3 2024Sep 30, 202463+27.3%Form 10-Q (regn-20250930.htm, filed 2025-10-28) ↗
Q2 2024Jun 30, 202456.5-3.4%Form 10-Q (regn-20250630.htm, filed 2025-08-01) ↗
Q1 2024Mar 31, 202455.9+12.0%Form 10-Q (regn-20250331.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 202352.7+10.7%Form 10-K (regn-20251231.htm; 0001804220-24-000040|regn-20240930.htm, filed 2026-02-04) ↗
Q3 2023Sep 30, 202349.5+2.9%Form 10-Q (regn-20240930.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 202358.5+23.7%Form 10-Q (regn-20240630.htm, filed 2024-08-01) ↗
Q1 2023Mar 31, 202349.9+31.3%Form 10-Q (regn-20240331.htm, filed 2024-05-02) ↗
Q4 2022Dec 31, 202247.6+29.0%Form 10-K (regn-20241231.htm; 0001804220-23-000031|regn-20230930.htm, filed 2025-02-05) ↗

Cite this data

StockData. (2026). Regeneron Pharmaceuticals Indirect R&D ($M), quarterly Q2 2018–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-indirect-lab

See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.

See a number that looks wrong?